logo

Concert Pharmaceuticals, Inc. (CNCE)



Trade CNCE now with
  Date
  Headline
6/12/2019 7:06:07 AM Concert Pharma Reports Positive Results From Phase 1 Studies Of CTP-692 In Healthy Volunteers
5/16/2019 7:10:42 AM Concert Pharma Begins New Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543
4/29/2019 7:15:38 AM Concert Pharma Names Jesper Høiland To Board
4/10/2019 6:36:42 AM Concert Pharma Initiates Phase 1 Multiple-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia
3/6/2019 7:19:53 AM Concert Pharma Begins Open Label Trial To Evaluate Once-Daily Vs. Twice-Daily Dosing Of CTP-543
3/1/2019 7:03:26 AM Concert Pharma Presents Interim CTP-543 Phase 2 Data In Alopecia Areata At AAD Annual Meeting
1/24/2019 7:07:36 AM Concert Begins Phase 1 Single-Ascending Dose Trial Of CTP-692 As An Adjunctive Treatment For Schizophrenia
1/22/2019 7:04:55 AM Concert Pharma Completes Enrollment Of 12 Mg Cohort In Phase 2a Trial Of CTP-543 In Alopecia Areata
12/17/2018 7:04:19 AM Concert Pharma Begins Phase 1 Program Of CTP-692 For Treatment Of Schizophrenia
11/1/2018 7:16:51 AM Concert Pharma Q3 Net Loss $17.4 Mln Or $0.74/shr Vs. Net Income $128.1 Mln Or $5.61/shr Last Year
8/2/2018 7:15:19 AM Concert Pharmaceuticals Q2 Loss/shr Narrows To $0.57 From $0.58 Last Year
5/3/2018 7:12:58 AM Concert Pharmaceuticals Q1 Net Loss $4.5 Mln Or $0.19/shr Vs. Net Loss $13.3 Mln Or $0.60/shr Last Year
4/25/2018 7:13:14 AM Concert Pharma Completes Enrollment In Phase 2a Trial Of CTP-543 In Alopecia Areata
3/1/2018 7:21:53 AM Concert Pharma FY17 Net Income $95.6 Mln Or $4.20/shr Vs. Net Loss $50.7 Mln Or $2.28/shr Last Year
1/12/2018 7:05:56 AM FDA Grants Fast Track Designation To Concert Pharmaceuticals’ CTP-543 For Treatment Of Alopecia Areata
1/12/2018 7:05:28 AM Concert Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding